News|Podcasts|November 17, 2026

ACT Brief: AI-Driven Coordinator Screening, Participant Pre-Screening Perceptions, and Three New FDA Approvals

In today’s ACT Brief, we examine how AI can cut coordinator screening time, how participants respond to AI-assisted pre-screening, and how FDA approved three new treatments.

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

  • In part three of a video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, explains how AI can unlock unstructured chart data and cut coordinator screening time from hours to minutes. He argues this matters for a clinical research workforce under strain.
  • A new study from Tufts CSDD surveyed 354 pre-screening respondents on AI-assisted and web-based trial pre-screening. Respondents rated AI voice-assisted screening, called Clara, favorably, and those users were more likely to schedule and attend study appointments than web-form users. Because respondents self-selected, the authors caution that the association cannot be read as causal.
  • FDA approved Genentech’s Gazyva as the first treatment for primary membranous nephropathy at risk of progression, based on the Phase III Majesty trial. In that trial, 36.1% of patients achieved complete remission of proteinuria at 104 weeks, compared with 5.7% on tacrolimus. The FDA also approved Alexion’s Klygefa for generalized myasthenia gravis, based on the Phase III Prevail trial.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.


Related to this article